Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00402766
First received: November 20, 2006
Last updated: March 4, 2014
Last verified: March 2014
  Purpose

Primary Objective:

  • To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma.

Secondary Objectives:

  • To explore the biologic effects of cisplatin, imatinib mesylate, and pemetrexed on tumor tissue by:
  • histologic analysis of biopsy tissue
  • by non-invasive assessments of tumor vascularity performed before, during and after treatment
  • electron microscopy analysis of endothelial cell architecture after patient treatment with imatinib mesylate
  • To explore the effects of cisplatin, imatinib mesylate, and pemetrexed on surrogate markers in serum.
  • To assess the rate of response to therapy.
  • To determine the doses of the combination regimen of cisplatin, imatinib mesylate, and pemetrexed that enables de-phosphorylation of platelet derived growth factor receptor (PDGF-R) on malignant mesothelioma tumor cells.
  • To determine the pharmacokinetic interaction between agents in this combination regimen.

Condition Intervention Phase
Mesothelioma
Drug: Cisplatin
Drug: Imatinib Mesylate
Drug: Pemetrexed
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Highest tolerable dose of drug combination (cisplatin, pemetrexed [Alimta®], and imatinib mesylate [Gleevec®]) that can be given to patients with unresectable or metastatic malignant mesothelioma. [ Time Frame: 4 Years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 42
Study Start Date: August 2006
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cisplatin + Imatinib + Pemetrexed
Cisplatin 60 mg/m^2 by vein, Over 2 Hours. Imatinib 300 mg PO Daily. Pemetrexed 500 mg/m^2 by vein, Over 40 Minutes.
Drug: Cisplatin
60 mg/m^2 by vein, Over 2 Hours
Other Names:
  • Platinol®-AQ
  • Platinol®
  • CDDP
Drug: Imatinib Mesylate
300 mg PO Daily
Other Names:
  • Gleevec
  • Imatinib
  • STI571
  • NSC-716051
Drug: Pemetrexed
500 mg/m^2 by vein, Over 40 Minutes
Other Names:
  • Alimta
  • LY231514
  • MTA
  • Multitargeted Antifolate
  • NSC-698037

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A written, voluntary informed consent form must be completed prior to beginning any study procedure.
  2. Patients >/= 18 years of age.
  3. Histologically documented diagnosis of malignant mesothelioma.
  4. Performance status 0-2 (ECOG)
  5. Patients must have adequate hepatic,renal,& bone marrow function,defined as the following:(1) total bilirubin </=1.5xULN;(2) SGOT & SGPT</=2.5xULN;(3)creatinine </= 1.5xULN;(4) ANC >/= 1.5x10^9/L;(5) platelets>/=100 x 10^9/L.Note:Renal function is only based on serum creatinine level </= 1.5xULN.The standard Cockcroft & Gault formula or the measured glomerular filtration rate (GFR) using the appropriate radio labelled method (51-CrEDTA or Tc99m-DTPA) must be used to calculate CrCl for enrollment or dosing.The same method used @ baseline should be used throughout the study.CrCl should be >/= 45mg/dl.
  6. Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  7. Patients who have not received prior chemotherapy for their metastatic or recurrent unresectable malignant mesothelioma; with the exception of patients who have recurrent mesothelioma after induction chemotherapy followed by definitive treatment (surgery +/- radiotherapy). Patients must have had 2 or fewer cycles/doses of induction chemotherapy and must have had tumor response to the induction therapy.
  8. Patients must have documented unresectable malignant mesothelioma (pleural or peritoneal).
  9. Patients with treated brain metastasis who have stable brain disease (i.e. no steroids at least 4 weeks prior to study enrollment).

Exclusion Criteria:

  1. Patient has received any other investigational agents within 28 days of first day of study drug dosing.
  2. Patient is </= 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer, squamous skin cancer, or a cervical carcinoma in situ.
  3. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure)
  4. Patients with myocardial infarction within 6 months of study.
  5. Female patients who are pregnant or breast-feeding.
  6. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
  7. Patient has a known untreated or unstable brain metastasis.
  8. Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
  9. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection. HIV patients are at much greater risk of infection when receiving highly myelosuppressive agents (cisplatin, pemetrexed, and imatinib) and for safety reasons are not eligible for this trial.
  10. Patient who received prior chemotherapy for their malignant mesothelioma with the exception listed in inclusion criteria #7.
  11. Patient previously received radiotherapy to >/= 25 % of the bone marrow.
  12. Patient had a major surgery within 2 weeks prior to study entry.
  13. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
  14. Patients must agree not to use herbal remedies or other over-the-counter biologics (i.e. shark cartilage).
  15. Prior exposure to imatinib mesylate.
  16. Patients taking therapeutic levels of warfarin. However, patients receiving 1 mg daily for catheter related anticoagulation are eligible for the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00402766

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Novartis
Investigators
Principal Investigator: Anne S. Tsao, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00402766     History of Changes
Other Study ID Numbers: 2005-0288, NCI-2012-01381
Study First Received: November 20, 2006
Last Updated: March 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:
Mesothelioma
Pleural Mesothelioma
Peritoneal Mesothelioma
PDGF-R
Pemetrexed
Alimta
Cisplatin
Imatinib Mesylate
Gleevec
Platinol
Platinol-AQ
CDDP
Ly231514
Multitargeted Antifolate
NSC-698037
STI571
NSSC-716051

Additional relevant MeSH terms:
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial
Pemetrexed
Imatinib
Cisplatin
Folic Acid Antagonists
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Protein Kinase Inhibitors

ClinicalTrials.gov processed this record on April 17, 2014